Upregulation of the ATR‐CHEK1 pathway in oral squamous cell carcinomas

The ATR‐CHEK1 pathway is upregulated and overactivated in Ataxia Telangiectasia (AT) cells, which lack functional ATM protein. Loss of ATM in AT confers radiosensitivity, although ATR‐CHEK1 pathway overactivation compensates, leads to prolonged G2 arrest after treatment with ionizing radiation (IR), and partially reverses the radiosensitivity. We observed similar upregulation of the ATR–CHEK1 pathway in a subset of oral squamous cell carcinoma (OSCC) cell lines with ATM loss. In the present study, we report copy number gain, amplification, or translocation of the ATR gene in 8 of 20 OSCC cell lines by FISH; whereas the CHEK1 gene showed copy number loss in 12 of 20 cell lines by FISH. Quantitative PCR showed overexpression of both ATR and CHEK1 in 7 of 11 representative OSCC cell lines. Inhibition of ATR or CHEK1 with their respective siRNAs resulted in increased sensitivity of OSCC cell lines to IR by the colony survival assay. siRNA‐mediated ATR or CHEK1 knockdown led to loss of G2 cell cycle accumulation and an increased sub‐G0 apoptotic cell population by flow cytometric analysis. In conclusion, the ATR‐CHEK1 pathway is upregulated in a subset of OSCC with distal 11q loss and loss of the G1 phase cell cycle checkpoint. The upregulated ATR‐CHEK1 pathway appears to protect OSCC cells from mitotic catastrophe by enhancing the G2 checkpoint. Knockdown of ATR and/or CHEK1 increases the sensitivity of OSCC cells to IR. These findings suggest that inhibition of the upregulated ATR–CHEK1 pathway may enhance the efficacy of ionizing radiation treatment of OSCC. © 2013 Wiley Periodicals, Inc.

[1]  Christine H Chung,et al.  Human Papillomavirus in Head and Neck Cancer: Its Role in Pathogenesis and Clinical Implications , 2009, Clinical Cancer Research.

[2]  Y. Shiloh.  ATM and related protein kinases: safeguarding genome integrity , 2003, Nature Reviews Cancer.

[3]  J. Lewis,et al.  Transoral laser microsurgery for oral squamous cell carcinoma: Oncologic outcomes and prognostic factors , 2014, Head & neck.

[4]  J. Bartek,et al.  DNA repair: Cyclin D1 multitasks , 2011, Nature.

[5]  E. Fredlund,et al.  Hypoxia-induced dedifferentiation of tumor cells--a mechanism behind heterogeneity and aggressiveness of solid tumors. , 2005, Seminars in cell & developmental biology.

[6]  Xin Huang,et al.  High-resolution mapping of the 11q13 amplicon and identification of a gene, TAOS1, that is amplified and overexpressed in oral cancer cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[7]  M. Romkes,et al.  Loss of distal 11q is associated with DNA repair deficiency and reduced sensitivity to ionizing radiation in head and neck squamous cell carcinoma , 2007, Genes, chromosomes & cancer.

[8]  C. Martin,et al.  The influence of clinical and demographic risk factors on the establishment of head and neck squamous cell carcinoma cell lines. , 2007, Oral oncology.

[9]  M. Meyn.  Ataxia‐telangiectasia, cancer and the pathobiology of the ATM gene , 1999, Clinical genetics.

[10]  M. Kastan,et al.  DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation , 2003, Nature.

[11]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[12]  A. Giaccia,et al.  Inhibition of ATR Leads to Increased Sensitivity to Hypoxia/Reoxygenation , 2004, Cancer Research.

[13]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[14]  Chen Bi,et al.  Abstract 1776: Antitumor activity of Chk1 inhibitor LY2606368 as a single agent in SW1990 human pancreas orthotopic tumor model , 2012 .

[15]  J. Sarkaria,et al.  Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines , 2011, British Journal of Cancer.

[16]  A. Cmelak,et al.  Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. , 2008, Journal of the National Cancer Institute.

[17]  M. Höglund,et al.  Cyclin D1 amplification in chromosomal band 11q13 is associated with overrepresentation of 3q21–q29 in head and neck carcinomas , 2002, International journal of cancer.

[18]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[19]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[20]  S. Gollin.  Chromosomal alterations in squamous cell carcinomas of the head and neck: Window to the biology of disease , 2001, Head & neck.

[21]  M. Ellis,et al.  Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. , 2012, The Journal of clinical investigation.

[22]  T. Glover,et al.  ATR Regulates Fragile Site Stability , 2002, Cell.

[23]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[24]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[25]  Jiri Bartek,et al.  The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair , 2005, Nature Cell Biology.

[26]  Joshua E. Elias,et al.  A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers , 2011, Nature.

[27]  Xiang Wang,et al.  An Overactivated ATR/CHK1 Pathway Is Responsible for the Prolonged G2 Accumulation in Irradiated AT Cells* , 2003, Journal of Biological Chemistry.

[28]  S. Gollin,et al.  Relationship between FRA11F and 11q13 gene amplification in oral cancer , 2007, Genes, chromosomes & cancer.

[29]  J. Manola,et al.  TP53 mutations and survival in squamous-cell carcinoma of the head and neck. , 2007, The New England journal of medicine.

[30]  R. Muschel,et al.  The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy , 2012, Cancer biology & therapy.

[31]  Erin L. Schenk,et al.  Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells In Vitro , 2012, Clinical Cancer Research.

[32]  A. Giaccia,et al.  ATR/ATM Targets Are Phosphorylated by ATR in Response to Hypoxia and ATM in Response to Reoxygenation* , 2003, The Journal of Biological Chemistry.

[33]  M. Meyn,et al.  Human fibroblasts transfected with an ATM antisense vector respond abnormally to ionizing radiation. , 1999, International journal of molecular medicine.

[34]  A. Giaccia,et al.  Hypoxia Links ATR and p53 through Replication Arrest , 2002, Molecular and Cellular Biology.

[35]  S. Taylor.  Head and neck cancer. , 1991, Cancer chemotherapy and biological response modifiers.

[36]  W. Cliby,et al.  Ataxia Telangiectasia Mutated (ATM) and ATM and Rad3-related Protein Exhibit Selective Target Specificities in Response to Different Forms of DNA Damage* , 2005, Journal of Biological Chemistry.

[37]  Thomas Ried,et al.  Chromosomal imbalances in oral squamous cell carcinoma: examination of 31 cell lines and review of the literature. , 2008, Oral oncology.

[38]  F. Toledo,et al.  A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs. , 1998, Molecular cell.

[39]  S. Petersen,et al.  Genetic imbalances with impact on survival in head and neck cancer patients. , 2000, The American journal of pathology.

[40]  Y. Shiloh.  ATM and ATR: networking cellular responses to DNA damage. , 2001, Current opinion in genetics & development.

[41]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[42]  J. Sarkaria,et al.  The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. , 2000, Cancer research.

[43]  M. McDevitt,et al.  Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias , 2012, Clinical Cancer Research.

[44]  T. Lawrence,et al.  Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1 , 2011, Cell cycle.